Key facts
- It has raised $3.5M; the latest was Early Stage VC ($11.7M) in Oct 2025.
- Notable investors include Caixa Capital Risc, Criteria Bio Ventures, Ekin + Program.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Adaptam Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Adaptam Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Adaptam Therapeutics
Developer of antibody-based therapies designed to overcome the immunosuppressive myeloid tumor microenvironment in cancer. The company offers targeted biologics against novel immune checkpoints, enabling oncology researchers and clinicians to advance more effective immunotherapies for hard-to-treat tumors.
- Sector
- Healthcare
- HQ
- Donostia-San Sebastian, Spain
- Founded
- 2021
- Employees
- 4
- Website
- adaptamtx.com/
- Ownership
- Privately Held (backing)
Adaptam Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adaptam Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adaptam Therapeutics in its N-PORT filings yet. We sweep new filings monthly.